NDC properties for "testosterone 1.62 % Transdermal Gel, 1.25 GM" (RxCUI 1597120)
About this data
The tables show NDC propoerties for testosterone 1.62 % Transdermal Gel, 1.25 GM with the RxCUI 1597120
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for testosterone 1.62 % Transdermal Gel, 1.25 GM (RxCUI 1597120)
| ANDA | ANDA204268 |
|---|---|
| ANDA | ANDA204570 |
| ANDA | ANDA205781 |
| MMSL_CODE | BD29532 |
| MMSL_CODE | CD29532 |
| RxCUI | 1597120 |
| SPL_SET_ID | 2d55b825-8eab-4091-bdf2-9c52d111b8eb |
| SPL_SET_ID | 4f3c2c0a-7dab-4b50-9cae-869c3c2a8498 |
| SPL_SET_ID | 54fcdcb9-fb0e-4164-9e51-f2a5feae3217 |
| VUID | 4038387 |
| Prescribable Synonym | testosterone 1.62 % (20.25MG / 1.25GM) Transdermal Gel |
| RXNAV_STR | 1250 MG testosterone 0.0162 MG/MG Topical Gel |
| RxNorm Name | 1250 MG testosterone 0.0162 MG/MG Topical Gel |
| RxNorm Synonym | testosterone 1.62 % Transdermal Gel, 1.25 GM |
| Related queries | Interactions (for RxCUI 1597120) |
NDC Properties
NDC Item 00591292530
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-30 |
| NDC Item | 00591292530 |
| Packaging | 30 PACKET in 1 CARTON (0591-2925-30) / 1.25 g in 1 PACKET (0591-2925-32) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 00591292532
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-32 |
| NDC Item | 00591292532 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 16714096801
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-01 |
| NDC Item | 16714096801 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 16714096802
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-02 |
| NDC Item | 16714096802 |
| Packaging | 30 PACKET in 1 CARTON (16714-968-02) / 1.25 g in 1 PACKET (16714-968-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 45802028103
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-03 |
| NDC Item | 45802028103 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802028139
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-39 |
| NDC Item | 45802028139 |
| Packaging | 30 PACKET in 1 CARTON (45802-281-39) / 1.25 g in 1 PACKET (45802-281-03) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802075403
| NDC 9 | 45802-754 |
|---|---|
| NDC 10 | 45802-754-03 |
| NDC Item | 45802075403 |
| Packaging | 1.25 g in 1 PACKET (45802-754-03) |
| ANDA | ANDA204268 |
| DCSA | CIII |
| FDA SPL set id | 602017 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2018-10-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-754 |
NDC Item 68382036212
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-12 |
| NDC Item | 68382036212 |
| Packaging | 1.25 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |
| Related queries | Properties for NDC 9 68382-362 |
NDC Item 00591292530
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-30 |
| NDC Item | 00591292530 |
| Packaging | 30 PACKET in 1 CARTON (0591-2925-30) / 1.25 g in 1 PACKET (0591-2925-32) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 00591292532
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-32 |
| NDC Item | 00591292532 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 16714096801
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-01 |
| NDC Item | 16714096801 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 16714096802
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-02 |
| NDC Item | 16714096802 |
| Packaging | 30 PACKET in 1 CARTON (16714-968-02) / 1.25 g in 1 PACKET (16714-968-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 45802028103
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-03 |
| NDC Item | 45802028103 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802028139
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-39 |
| NDC Item | 45802028139 |
| Packaging | 30 PACKET in 1 CARTON (45802-281-39) / 1.25 g in 1 PACKET (45802-281-03) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802075403
| NDC 9 | 45802-754 |
|---|---|
| NDC 10 | 45802-754-03 |
| NDC Item | 45802075403 |
| Packaging | 1.25 g in 1 PACKET (45802-754-03) |
| ANDA | ANDA204268 |
| DCSA | CIII |
| FDA SPL set id | 602017 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2018-10-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-754 |
NDC Item 68382036212
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-12 |
| NDC Item | 68382036212 |
| Packaging | 1.25 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |
| Related queries | Properties for NDC 9 68382-362 |
NDC Item 00591292530
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-30 |
| NDC Item | 00591292530 |
| Packaging | 30 PACKET in 1 CARTON (0591-2925-30) / 1.25 g in 1 PACKET (0591-2925-32) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 00591292532
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-32 |
| NDC Item | 00591292532 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 16714096801
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-01 |
| NDC Item | 16714096801 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 16714096802
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-02 |
| NDC Item | 16714096802 |
| Packaging | 30 PACKET in 1 CARTON (16714-968-02) / 1.25 g in 1 PACKET (16714-968-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 45802028103
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-03 |
| NDC Item | 45802028103 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802028139
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-39 |
| NDC Item | 45802028139 |
| Packaging | 30 PACKET in 1 CARTON (45802-281-39) / 1.25 g in 1 PACKET (45802-281-03) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802075403
| NDC 9 | 45802-754 |
|---|---|
| NDC 10 | 45802-754-03 |
| NDC Item | 45802075403 |
| Packaging | 1.25 g in 1 PACKET (45802-754-03) |
| ANDA | ANDA204268 |
| DCSA | CIII |
| FDA SPL set id | 602017 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2018-10-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-754 |
NDC Item 68382036212
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-12 |
| NDC Item | 68382036212 |
| Packaging | 1.25 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |
| Related queries | Properties for NDC 9 68382-362 |
NDC Item 00591292530
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-30 |
| NDC Item | 00591292530 |
| Packaging | 30 PACKET in 1 CARTON (0591-2925-30) / 1.25 g in 1 PACKET (0591-2925-32) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 00591292532
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-32 |
| NDC Item | 00591292532 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 16714096801
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-01 |
| NDC Item | 16714096801 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 16714096802
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-02 |
| NDC Item | 16714096802 |
| Packaging | 30 PACKET in 1 CARTON (16714-968-02) / 1.25 g in 1 PACKET (16714-968-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 45802028103
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-03 |
| NDC Item | 45802028103 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802028139
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-39 |
| NDC Item | 45802028139 |
| Packaging | 30 PACKET in 1 CARTON (45802-281-39) / 1.25 g in 1 PACKET (45802-281-03) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802075403
| NDC 9 | 45802-754 |
|---|---|
| NDC 10 | 45802-754-03 |
| NDC Item | 45802075403 |
| Packaging | 1.25 g in 1 PACKET (45802-754-03) |
| ANDA | ANDA204268 |
| DCSA | CIII |
| FDA SPL set id | 602017 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2018-10-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-754 |
NDC Item 68382036212
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-12 |
| NDC Item | 68382036212 |
| Packaging | 1.25 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |
| Related queries | Properties for NDC 9 68382-362 |
NDC Item 00591292530
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-30 |
| NDC Item | 00591292530 |
| Packaging | 30 PACKET in 1 CARTON (0591-2925-30) / 1.25 g in 1 PACKET (0591-2925-32) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 00591292532
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-32 |
| NDC Item | 00591292532 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 16714096801
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-01 |
| NDC Item | 16714096801 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 16714096802
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-02 |
| NDC Item | 16714096802 |
| Packaging | 30 PACKET in 1 CARTON (16714-968-02) / 1.25 g in 1 PACKET (16714-968-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 45802028103
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-03 |
| NDC Item | 45802028103 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802028139
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-39 |
| NDC Item | 45802028139 |
| Packaging | 30 PACKET in 1 CARTON (45802-281-39) / 1.25 g in 1 PACKET (45802-281-03) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802075403
| NDC 9 | 45802-754 |
|---|---|
| NDC 10 | 45802-754-03 |
| NDC Item | 45802075403 |
| Packaging | 1.25 g in 1 PACKET (45802-754-03) |
| ANDA | ANDA204268 |
| DCSA | CIII |
| FDA SPL set id | 602017 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2018-10-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-754 |
NDC Item 68382036212
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-12 |
| NDC Item | 68382036212 |
| Packaging | 1.25 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |
| Related queries | Properties for NDC 9 68382-362 |
NDC Item 00591292530
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-30 |
| NDC Item | 00591292530 |
| Packaging | 30 PACKET in 1 CARTON (0591-2925-30) / 1.25 g in 1 PACKET (0591-2925-32) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 00591292532
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-32 |
| NDC Item | 00591292532 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 16714096801
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-01 |
| NDC Item | 16714096801 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 16714096802
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-02 |
| NDC Item | 16714096802 |
| Packaging | 30 PACKET in 1 CARTON (16714-968-02) / 1.25 g in 1 PACKET (16714-968-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 45802028103
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-03 |
| NDC Item | 45802028103 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802028139
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-39 |
| NDC Item | 45802028139 |
| Packaging | 30 PACKET in 1 CARTON (45802-281-39) / 1.25 g in 1 PACKET (45802-281-03) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802075403
| NDC 9 | 45802-754 |
|---|---|
| NDC 10 | 45802-754-03 |
| NDC Item | 45802075403 |
| Packaging | 1.25 g in 1 PACKET (45802-754-03) |
| ANDA | ANDA204268 |
| DCSA | CIII |
| FDA SPL set id | 602017 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2018-10-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-754 |
NDC Item 68382036212
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-12 |
| NDC Item | 68382036212 |
| Packaging | 1.25 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |
| Related queries | Properties for NDC 9 68382-362 |
NDC Item 00591292530
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-30 |
| NDC Item | 00591292530 |
| Packaging | 30 PACKET in 1 CARTON (0591-2925-30) / 1.25 g in 1 PACKET (0591-2925-32) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 00591292532
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-32 |
| NDC Item | 00591292532 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 16714096801
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-01 |
| NDC Item | 16714096801 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 16714096802
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-02 |
| NDC Item | 16714096802 |
| Packaging | 30 PACKET in 1 CARTON (16714-968-02) / 1.25 g in 1 PACKET (16714-968-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 45802028103
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-03 |
| NDC Item | 45802028103 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802028139
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-39 |
| NDC Item | 45802028139 |
| Packaging | 30 PACKET in 1 CARTON (45802-281-39) / 1.25 g in 1 PACKET (45802-281-03) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802075403
| NDC 9 | 45802-754 |
|---|---|
| NDC 10 | 45802-754-03 |
| NDC Item | 45802075403 |
| Packaging | 1.25 g in 1 PACKET (45802-754-03) |
| ANDA | ANDA204268 |
| DCSA | CIII |
| FDA SPL set id | 602017 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2018-10-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-754 |
NDC Item 68382036212
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-12 |
| NDC Item | 68382036212 |
| Packaging | 1.25 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |
| Related queries | Properties for NDC 9 68382-362 |
NDC Item 00591292530
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-30 |
| NDC Item | 00591292530 |
| Packaging | 30 PACKET in 1 CARTON (0591-2925-30) / 1.25 g in 1 PACKET (0591-2925-32) |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 00591292532
| NDC 9 | 0591-2925 |
|---|---|
| NDC 10 | 0591-2925-32 |
| NDC Item | 00591292532 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA204570 |
| DCSA | CIII |
| FDA SPL set id | 546325 |
| Labeler | Actavis Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2021-02-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 0591-2925 |
NDC Item 16714096801
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-01 |
| NDC Item | 16714096801 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 16714096802
| NDC 9 | 16714-968 |
|---|---|
| NDC 10 | 16714-968-02 |
| NDC Item | 16714096802 |
| Packaging | 30 PACKET in 1 CARTON (16714-968-02) / 1.25 g in 1 PACKET (16714-968-01) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 775662 |
| Labeler | Northstar Rx LLC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-11-06 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 16714-968 |
NDC Item 45802028103
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-03 |
| NDC Item | 45802028103 |
| Packaging | 1.25 g in 1 PACKET |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802028139
| NDC 9 | 45802-281 |
|---|---|
| NDC 10 | 45802-281-39 |
| NDC Item | 45802028139 |
| Packaging | 30 PACKET in 1 CARTON (45802-281-39) / 1.25 g in 1 PACKET (45802-281-03) |
| ANDA | ANDA205781 |
| DCSA | CIII |
| FDA SPL set id | 784981 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2019-06-27 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-281 |
NDC Item 45802075403
| NDC 9 | 45802-754 |
|---|---|
| NDC 10 | 45802-754-03 |
| NDC Item | 45802075403 |
| Packaging | 1.25 g in 1 PACKET (45802-754-03) |
| ANDA | ANDA204268 |
| DCSA | CIII |
| FDA SPL set id | 602017 |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Marketing effective time low | 2018-10-12 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 45802-754 |
NDC Item 68382036212
| NDC 9 | 68382-362 |
|---|---|
| NDC 10 | 68382-362-12 |
| NDC Item | 68382036212 |
| Packaging | 1.25 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 676429 |
| Labeler | Zydus Pharmaceuticals (USA) Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Marketing effective time high | 2021-08-31 |
| Marketing effective time low | 2018-10-12 |
| Marketing status | COMPLETED |
| NDA_AUTHORIZED_GENERIC | NDA022309 |
| Related queries | Properties for NDC 9 68382-362 |